spacer
home > ict > autumn 2020 > direct-to-patient trials – improving patient engagement
PUBLICATIONS
International Clinical Trials

Direct-to-Patient Trials – Improving Patient Engagement

Society is evolving rapidly, especially in response to the COVID-19 pandemic. New technologies are changing the way we communicate, and vast amounts of information are readily available, introducing a new era of personalisation. This has resulted in patient needs becoming the focus of clinical studies. With patients taking more control of their own health and treatment options, the advantages and challenges of different trial methods are magnified.

A Patient-Centric Clinical Trial Model

The traditional method of patients visiting their clinical trial site to pick up medication can disrupt the patient’s day-to-day life. Today, this can be minimised by sponsors implementing a direct-to-patient (DtP) model into their study design.

With clinical supplies prepared, packaged, labelled, and then shipped directly to the home of the patient or caregiver, DtP ensures that trial participants are no longer required to visit the clinical site, which has become even more challenging in light of COVID-19.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sarah Halmrast has 20 years’ experience in project management, primarily in clinical supplies. She initially joined CSM, which later became part of Clinigen Group, as a pharmacy technician and held various roles within the company before becoming the Vice President, Global Project Management, in 2018. Leading the Project Management departments in the US and the EU, her role is critical to ensure harmonisation of practices for clients to experience the same service levels, regardless of their geographical location. Sarah has a Pharmacy Technician degree from North Dakota State College of Science, US, and a Bachelor’s degree in Business Management from the University of Mary, US.

shalmrast@csmondemand.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Purification specialist BIA Separations to become part of Sartorius

Combination of businesses will create a premium portfolio for advanced therapies BIA Separations will be Sartorius’ center of excellence for purification of cell and gene therapeutics
More info >>

White Papers

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

Sartorius Group

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement